Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

MLA

Laura Solán, et al. “Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide.” Frontiers in Immunology, vol. 12, Feb. 2021. EBSCOhost, https://doi.org/10.3389/fimmu.2021.516078.

APA

Laura Solán, Diego Carbonell, Paula Muñiz, Nieves Dorado, Elena Landete, María Chicano-Lavilla, Javier Anguita, Jorge Gayoso, Mi Kwon, José Luis Díez-Martín, Carolina Martínez-Laperche, & Ismael Buño. (2021). Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.516078

Chicago

Laura Solán, Diego Carbonell, Paula Muñiz, Nieves Dorado, Elena Landete, María Chicano-Lavilla, Javier Anguita, et al. 2021. “Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide.” Frontiers in Immunology 12 (February). doi:10.3389/fimmu.2021.516078.